FDA Brief

Warning letters Drugs

FDA warning letter to

Royal Peptides LLC

High riskIssued Aug 24Posted Sep 1Center for Drug Evaluation and Research (CDER)

FDA warned Royal Peptides LLC that seven peptide products sold on its website are unapproved new drugs.

What happened

FDA reviewed the company's website, royal-peptides.com, in July 2026 rather than doing an inspection. FDA found the site selling seven peptide products with claims that they treat disease or change body function, such as weight loss, blood sugar control and sexual dysfunction, and found no FDA-approved application for any of them. FDA also noted that the site markets bacteriostatic water (water used to mix injectable drugs) together with a "peptide guide" and "peptide calculator," which the agency says shows the products are meant for human injection despite "research use only" labels.

What FDA found

  1. The company sells seven peptide products that FDA has not approved, and shipping them across state lines breaks the law.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  2. Website wording that the products cause weight loss, improve insulin and glucose control, or treat sexual dysfunction makes them drugs in FDA's view.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128
  3. The products are not generally recognized as safe and effective for their labeled uses, so they are "new drugs" that need an approved application.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  4. Saying products are "for research use only" and "not for human or animal consumption" does not undo the drug claims on the website, including selling mixing water with a peptide guide and calculator.

What FDA wants

FDA tells the company to write to FDAAdvisory@fda.hhs.gov within 15 business days with the steps taken to fix each violation, how it will keep them from happening again, and supporting documents. The reply must carry reference number 734884 in the subject line.

Who should pay attention

  • clinics and med spas that buy peptides from online sellers
  • consumers who order injectable peptides online
  • peptide distributors and compounding pharmacies selling similar products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk